Development of a novel combination tablet containing trimebutine maleate and mosapride citrate for the treatment of functional dyspepsia

To develop a novel combination tablet which contained 100 mg trimebutine maleate and 5 mg mosapride citrate (TMCT) for the treatment of functional dyspepsia, the wet granulation method was used to prepare TMCTs with various amounts of diluents and stabilizers. The levels of impurities, the stability and the dissolution of the TMCTs were investigated. The oral bioavailability of drugs in the TMCTs was then evaluated and compared to the simultaneous oral administration of trimebutine maleate-loaded and mosapride citrate-loaded commercial products in the beagle dog. Among the diluents tested, d-mannitol was selected, since the microcrystalline cellulose and lactose did not inhibit the production of drug impurities due to their hygroscopic properties and chemical interactions, respectively. Furthermore, succinic acid was selected as the stabilizer because it gave the lowest level of total drug impurities of the organic acids tested. The combination tablet of trimebutine maleate and mosapride citrate prepared with D-mannitol and succinic acid gave a total drug content higher than 95% and total impurities lower than 0.5% at 25 °C/60% RH and 40 °C/75% RH during a 6-month period, indicating that the tablets were stable for at least 6 months. Furthermore, this combination tablet showed a similar dissolution to the trimebutine maleate-loaded and mosapride citrate-loaded commercial products and gave insignificantly different absorption compared to these commercial products in beagle dogs. Thus, the combination tablet of trimebutine maleate and mosapride citrate prepared with d-mannitol and succinic acid would be a stable and effective oral pharmaceutical product for the treatment of functional dyspepsia.

Blood concentration–time profiles of trimebutine maleate and mosapride citrate after oral administration of TMCT or simultaneous oral administration of trimebutine maleate-loaded and mosapride citrate-loaded commercial products at the equivalent dose of 200 mg trimebutine maleate and 10 mg mosapride citrate in the beagle dog: (A) trimebutine maleate and (B) mosapride citrate. Each value represents the mean ± S.D. (n = 8).Figure optionsDownload as PowerPoint slide